Post‐ABVD biopsy results, and not post‐ABVD FDG‐PET results, predict outcome in early‐stage Hodgkin lymphoma

Abstract

Bao, W., Bussel, J.B., Heck, S., He, W., Karpoff, M., Boulad, K. & Yazdanbakhsh, K. (2010) Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood, 116, 4639– 4645. Efficace, F., Mandelli, F., Fazi, P., Santoro, C., Gaidano, G., Cottone, F., Borchiellini, A., Carpenedo, M., Simula, M.P., Di Giacomo, V., Bergamaschi, M., Vincelli, I.D., Rodeghiero, F., Ruggeri, M., Scaramucci, L., Rambaldi, A., Cascavilla, N., Forghieri, F., Petrungaro, A., Ditonno, P., Caocci, G., Cirrincione, S. & Mazzucconi, M.G. (2016) Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 91, 995–1001. G omez-Almaguer, D., Tar ın-Arzaga, L., MorenoJaime, B., Jaime-P erez, J.C., Ceballos-L opez, A.A., Ruiz-Arg€ uelles, G.J., Ruiz-Delgado, G.J., Cant u-Rodr ıguez, O.G., Guti errez-Aguirre, C.H. & S anchez-C ardenas, M. (2013) High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 90, 494–500. G omez-Almaguer, D., Herrera-Rojas, M.A., JaimeP erez, J.C., G omez-De Le on, A., Cant uRodr ıguez, O.G., Guti errez-Aguirre, C.H., Tar ınArzaga, L., Hern andez-Reyes, J. & RuizArguelles, G.J. (2014) Eltrombopag and highdose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood, 123, 3906–3908. Gonz alez-L opez, T.J., Fern andez-Fuertes, F., Hern andez-Rivas, J.A., S anchez-Gonz alez, B., Mart ınez-Robles, V., Alvarez-Rom an, M.T., P erez-Rus, G., Pascual, C., Bernat, S., ArrietaCerd an, E., Aguilar, C., B arez, A., Pe~ narrubia, M.J., Olivera, P., Fern andez-Rodr ıguez, A., de Cabo, E., Garc ıa-Frade, L.J. & Gonz alez-Porras, J.R. (2017) Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. International Journal of Hematology, 106, 508–516. Lambert, M.P. & Gernsheimer, T.B. (2017) Clinical updates in adult immune thrombocytopenia. Blood, 129, 2829–2835. Rodeghiero, F., Michel, M., Gernsheimer, T., Ruggeri, M., Blanchette, V., Bussel, B., Cines, D.B., Cooper, N., Godeau, B., Greinacher, A., Imbach, P., Khellaf, M., Klaassen, R.J., K€ uhne, T., Liebman, H., Mazzucconi, M.G., Newland, A., Pabinger, I., Tosetto, A. & Stasi, R. (2013) Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 121, 2596–2606. Tripathi, A.K., Shukla, A., Mishra, S., Yadav, Y.S. & Yadav, D.K. (2014) Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. International Journal of Hematology, 99, 413–417. Wei, Y., Ji, X.B., Wang, Y.W., Wang, J.X., Yang, E.Q., Wang, Z.C., Sang, Y.Q., Bi, Z.M., Ren, C.A., Zhou, F., Liu, G.Q., Peng, J. & Hou, M. (2016) High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood, 127, 296–302. Zaja, F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., Campagna, S., Ferrara, F., Angelucci, E., Usala, E., Cantoni, S., Visani, G., Rizzi, R., Stefano, V.De, Casulli, F., Battista, M.L., Isola, M., Soldano, F., Gamba, E. & Fanin, R. (2010) Dexamethasone plus rituiximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood, 115, 2755– 2762.